Stay updated with breaking news from Nasdaq Phvs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharvaris (NASDAQ:PHVS – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $34.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 64.65% from the stock’s previous […]
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin...
JMP Securities reissued their market outperform rating on shares of Pharvaris (NASDAQ:PHVS – Free Report) in a research note released on Wednesday, Benzinga reports. JMP Securities currently has a $49.00 price target on the stock. Several other equities analysts also recently issued reports on the stock. Wedbush decreased their price objective on shares of Pharvaris […]
Pharvaris (NASDAQ:PHVS – Free Report) had its price target hoisted by JMP Securities from $40.00 to $49.00 in a research report released on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Other analysts also recently issued research reports about the stock. Wedbush decreased their price target on shares of […]
Pharvaris (NASDAQ:PHVS – Get Free Report) had its price objective increased by equities research analysts at JMP Securities from $40.00 to $49.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price target indicates a potential upside of 68.97% from […]